Oncology Congress

CME/CE INFORMATION

Oncology Congress

Saturday, April 13, 2024 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT

HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it.
Step 2: Complete Evaluation(s)
Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
Step 3: View and Print Certificate(s)
After you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.

For Pharmacists: Upon completion of the online evaluation(s), your credits will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluations and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

PARP Inhibitors in Prostate Cancer: Practical Application of Recent Advances
to Ensure Equitable Care in Rural and Underserved Populations

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

Describe the mechanism of action and clinical rationale for using PARP inhibitors in the management of metastatic castration-resistant prostate cancer (mCRPC)
Evaluate recent clinical trial data for novel and emerging PARP inhibitor therapy for mCRPC
Integrate the latest data and expert guidance on PARP inhibitor therapy to develop personalized treatment plans for patients with mCRPC
Employ interprofessional strategies to overcome barriers and support equitable prostate cancer care in rural and underserved populations

FACULTY
Neeraj Agarwal, MD, FASCO
Professor of Medicine
Senior Director of Clinical Research
Director, Genitourinary Oncology Program
NCICCC Huntsman Cancer Institute, University of Utah
Salt Lake City, UT

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-028-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Neeraj Agarwal, MD, FASCO, has disclosed the following relevant financial relationships: contracted research (awarded to institution) from Arvinas, Inc., Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Bayer Corporation, Bristol Meyers Squibb, Calithera Biosciences, Celldex Therapeutics, Inc., CRISPR Therapeutics, Eisai Co., Ltd., Eli Lilly and Company, EMD Serono, Inc., Exelixis, Inc., Genentech, Inc., Gilead Sciences, Inc., GSK, Immunomedics, Inc. (now Gilead Sciences, Inc.), Janssen Pharmaceuticals, LAVA Therapeutics, Merck & Co., Inc., Nektar Therapeutics, Neoleukin Therapeutics, Inc., Novartis Pharmaceuticals, ORIC Pharmaceuticals, Pfizer, Inc., Roche, Sanofi, Seattle Genetics, and TRACON Pharmaceuticals, Inc.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Optimizing Risk Stratification and Management of Myelodysplastic Syndrome:
Strategies for Improving Equitable Access to Care in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported through an educational grant from Bristol Myers Squibb.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Utilize appropriate diagnostic techniques and risk stratification to determine optimal management strategies for patients with myelodysplastic syndrome (MDS)
Apply patient-centered strategies for improving the management and monitoring of patients with MDS
Integrate current evidence into decisions about first-line treatment of anemia in patients with lower-risk MDS who have not previously been treated with erythropoietin-stimulating agents and may require blood transfusions
Evaluate the safety and efficacy of new and emerging therapies for MDS
Employ evidence-based strategies for improving access to care and collaborative management of patients with MDS who reside in rural and underserved communities

FACULTY
Rami S. Komrokji, MD
Vice Chair, Department of Malignant Hematology
Section Head, Leukemia and MDS
Moffitt Cancer Center
Professor, Department of Oncologic Sciences
University of South Florida
Tampa, FL

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Rami S. Komrokji, MD, has disclosed the following relevant financial relationships: speakers’ bureau/advisory board for AbbVie, Inc., Bristol Myers Squibb, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, PharmaEssentia, Rigel Pharmaceuticals, Inc., Servier, Sobi, and Sumitomo Pharma Co., Ltd.; research/grant support from Bristol Myers Squibb; consultant for Geron, Janssen Pharmaceuticals, and Sumitomo Pharma Co., Ltd.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Gastric and Gastroesophageal Cancer: Navigating the Evolving
Treatment Landscape to Optimize Care and Advance Health Equity

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Explain the role of biomarkers in gastric/gastroesophageal (GEJ) cancers to guide diagnosis and treatment decisions
Describe the mechanism of action of emerging systemic therapies for unresectable locally advanced or metastatic gastric/GEJ cancers
Evaluate clinical evidence on the safety and efficacy of current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers
Implement team-based strategies for monitoring and managing adverse events associated with systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers

FACULTY
Yelena Y. Janjigian, MD
Professor of Medicine
Weill Cornell Medical College
Chief Attending, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Yelena Y. Janjigian, MD, has disclosed the following relevant financial relationships: advisory board member/consultant for AbbVie, Inc., AmerisourceBergen (now Cencora, Inc.), AskGene Pharma, Inc., Arcus Biosciences, Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly and Company, Geneos Therapeutics, Inc., GSK, Guardant Health, Inc., Imugene, Inspirna, Merck & Co., Inc., Merck Serono, Mersana Therapeutics, Inc., Pfizer, Inc., Sanofi Genzyme, Seagen, Inc., Silverback Therapeutics (now ARS Pharmaceuticals), and Zymeworks, Inc.; speakers’ bureau for AbbVie, Inc., Amerisource Bergen (now Cencora, Inc.), AskGene Pharma, Inc., Arcus Biosciences, Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly and Company, Geneos Therapeutics, Inc., GSK, Guardant Health, Inc., Imugene, Inspirna, Lynx Health, Merck & Co., Inc., Merck Serono, Mersana Therapeutics, Inc., Pfizer, Inc., Sanofi Genzyme, Seagen, Inc., Silverback Therapeutics (now ARS Pharmaceuticals), and Zymeworks Inc.; research/grant support from Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Arcus Biosciences, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc./Roche, Inspirna, Merck & Co., Inc., and Transcenta; stock ownership interest in Inspirna.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Advances in HER2-Mutant Non-Small Cell Lung Cancer (NSCLC):
Optimizing Outcomes in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Apply guideline-recommended genomic testing to identify actionable driver mutations, including HER2 activating mutations, and inform treatment decisions in patients with NSCLC
Integrate the latest clinical evidence on HER2-directed agents into treatment plans for patients with HER2-altered advanced NSCLC
Employ collaborative strategies for the prevention and management of common and serious treatment-related adverse events in patients with NSCLC receiving HER2-directed agents

FACULTY
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Lee Albright and Nile Albright MD Endowed Chair, Clinical Cancer Research
Massachusetts General Hospital Cancer Center
Boston, MA

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Rebecca S. Heist, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., CLaiM Therapeutics, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi; contracted research (awarded to institution) for AbbVie, Inc., Agios Pharmaceuticals, Corvus Pharmaceuticals, Daiichi Sankyo, Inc., Eli Lilly and Company, Erasca, Inc., Mirati Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc. (now Bristol Myers Squibb).

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

TROP2-Targeted Antibody-Drug Conjugates in NSCLC:
An Update for Oncologists who Serve Patients in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Describe the role of TROP2 as a potential therapeutic target in patients with non-small cell lung cancer (NSCLC) and the rationale for using antibody-drug conjugates to target this marker
Evaluate the current safety and efficacy data related to TROP2-directed antibody-drug conjugates for the treatment of NSCLC
Implement strategies to address disparities in lung cancer care, testing, and treatment in rural and underserved communities

FACULTY
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chair, Clinical Cancer Research
Massachusetts General Hospital Cancer Center
Boston, MA

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Rebecca S. Heist, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., CLaiM Therapeutics, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi; contracted research (awarded to institution) for AbbVie, Inc., Agios Pharmaceuticals, Corvus Pharmaceuticals, Daiichi Sankyo, Inc., Erasca, Inc., Eli Lilly and Company, Mirati Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc. (now Bristol Myers Squibb).

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Improving Equity in Hepatocellular Carcinoma Care:
Integrating Evolving Treatment Approaches in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by an independent medical education grant from AstraZeneca Pharmaceuticals.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Assess the efficacy and safety of immunotherapies and combination therapy approaches for unresectable hepatocellular carcinoma (HCC)
Integrate clinical evidence and current guideline recommendations on immunotherapies and combination therapy into treatment plans for patients with unresectable HCC
Implement interprofessional strategies for reducing disparities in care access and treatment for HCC in rural and underserved settings

FACULTY
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Ghassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Agenus, Inc., Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Inc., Genentech, Inc./Roche, Helsinn, Parker Institute for Cancer Immunotherapy, Pertzye - Digestive Care, Inc., Puma Biotechnology, Inc., QED Therapeutics, Servier Pharmaceuticals, and Yiviva; consultant/advisory board member for AbbVie, Inc., AstraZeneca Pharmaceuticals, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Inc., Exelixis, Inc., Genentech, Inc./Roche, Incyte Corporation, Ipsen, J-Pharma Co., Ltd., Merck & Co., Inc., Merus, Neogene Therapeutics, Novartis Pharmaceuticals Corporation, Servier Pharmaceuticals, Tempus, Vector Pharma, and Yiviva.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

CONTACT US

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

System checker: Must meet all requirements of BroadcastMed Live Events Platform
Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.